| Aktie | Ticker | Breite | GCS | 2026/Q2 | 2026/Q1 | 2025/Q4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 117.413.190 $ | +52.629.622 $ | -2,0 % | 74 | 70.867.716 $ | +40.339.176 $ | -22,7 % | 78 | 44.153.671 $ | +44.153.671 $ | 84 | |||||
| SPDR SERIES TRUST | → 0 | 90.202.500 $ | +53.812.223 $ | +147,9 % | 1 | 36.390.277 $ | +36.390.277 $ | 1 | |||||||
| SERA PROGNOSTICS, INC. | SERA | → 0 | 4.865.271 $ | +4.865.271 $ | 1 | ||||||||||
| Definium Therapeutics, Inc. | DFTX | → 0 | Neutral | 470.400 $ | -187.320 $ | -28,5 % | 1 | 657.720 $ | +191.199 $ | +41,0 % | 1 | 466.521 $ | +466.521 $ | 1 | |
| Royalty Pharma plc | RPRX | → 0 | Neutral | 616.770 $ | +89.100 $ | +16,9 % | 1 | 527.670 $ | -6.567 $ | -1,2 % | 1 | 534.237 $ | +534.237 $ | 1 | |
| Tyra Biosciences, Inc. | TYRA | → 0 | Schwach | 612.800 $ | +38.285 $ | +6,7 % | 1 | 574.515 $ | +574.515 $ | 1 | |||||
| Nurix Therapeutics, Inc. | NRIX | → 0 | Neutral | 606.500 $ | +161.650 $ | +36,3 % | 1 | 444.850 $ | -99.836 $ | -18,3 % | 1 | 544.686 $ | +544.686 $ | 1 | |
| INCYTE CORP | INCY | → 0 | Neutral | 600.808 $ | +101.972 $ | +20,4 % | 1 | 498.836 $ | -29.584 $ | -5,6 % | 1 | 528.420 $ | +528.420 $ | 1 | |
| ARGENX SE | ARGX | → 0 | 594.701 $ | +126.611 $ | +27,0 % | 1 | 468.090 $ | -61.709 $ | -11,6 % | 1 | 529.799 $ | +529.799 $ | 1 | ||
| Disc Medicine, Inc. | IRON | → 0 | Neutral | 585.120 $ | +73.600 $ | +14,4 % | 1 | 511.520 $ | +511.520 $ | 1 | |||||
| Praxis Precision Medicines, Inc. | PRAX | → 0 | Sehr schwach | 483.285 $ | -100.890 $ | -17,3 % | 1 | 584.175 $ | +584.175 $ | 1 | |||||
| Travere Therapeutics, Inc. | TVTX | → 0 | Neutral | 583.543 $ | +583.543 $ | 1 | |||||||||
| Rapport Therapeutics, Inc. | RAPP | → 0 | Schwach | 583.380 $ | +145.320 $ | +33,2 % | 1 | 438.060 $ | -93.072 $ | -17,5 % | 1 | 531.132 $ | +531.132 $ | 1 | |
| Ascendis Pharma A/S | ASND | → 0 | 400.080 $ | -171.745 $ | -30,0 % | 1 | 571.825 $ | +21.879 $ | +4,0 % | 1 | 549.946 $ | +549.946 $ | 1 | ||
| Pharvaris N.V. | PHVS | → 0 | Stark | 518.700 $ | -46.300 $ | -8,2 % | 1 | 565.000 $ | -4.180 $ | -0,7 % | 1 | 569.180 $ | +569.180 $ | 1 | |
| Ultragenyx Pharmaceutical Inc. | RARE | → 0 | Neutral | 567.630 $ | +104.635 $ | +22,6 % | 1 | 462.995 $ | +462.995 $ | 1 | |||||
| Trevi Therapeutics, Inc. | TRVI | → 0 | Neutral | 559.500 $ | +201.600 $ | +56,3 % | 1 | 357.900 $ | +357.900 $ | 1 | |||||
| Monte Rosa Therapeutics, Inc. | GLUE | → 0 | Schwach | 556.600 $ | +96.000 $ | +20,8 % | 1 | 460.600 $ | +460.600 $ | 1 | |||||
| Jazz Pharmaceuticals plc | JAZZ | → 0 | Schwach | 233.982 $ | -319.878 $ | -57,8 % | 1 | 553.860 $ | +553.860 $ | 1 | |||||
| Celldex Therapeutics, Inc. | CLDX | → 0 | Neutral | 483.730 $ | +71.370 $ | +17,3 % | 1 | 412.360 $ | -140.835 $ | -25,5 % | 1 | 553.195 $ | +553.195 $ | 1 | |
| CG Oncology, Inc. | CGON | → 0 | Schwach | 551.925 $ | +551.925 $ | 1 | |||||||||
| BELITE BIO, INC | BLTE | → 0 | Neutral | 550.742 $ | +550.742 $ | 1 | |||||||||
| TG THERAPEUTICS, INC. | TGTX | → 0 | Neutral | 549.400 $ | +117.540 $ | +27,2 % | 1 | 431.860 $ | -98.967 $ | -18,6 % | 1 | 530.827 $ | +530.827 $ | 1 | |
| Apellis Pharmaceuticals, Inc. | APLS | → 0 | 549.274 $ | +549.274 $ | 1 | ||||||||||
| HALOZYME THERAPEUTICS, INC. | HALO | → 0 | Neutral | 547.890 $ | +29.170 $ | +5,6 % | 1 | 518.720 $ | -21.430 $ | -4,0 % | 1 | 540.150 $ | +540.150 $ | 1 | |
| Terns Pharmaceuticals, Inc. | TERN | → 0 | 547.824 $ | +547.824 $ | 1 | ||||||||||
| Revolution Medicines, Inc. | RVMD | → 0 | Neutral | 224.736 $ | -322.619 $ | -58,9 % | 1 | 547.355 $ | +547.355 $ | 1 | |||||
| Centessa Pharmaceuticals plc | CNTA | → 0 | 547.194 $ | +547.194 $ | 1 | ||||||||||
| CYTOKINETICS INC | CYTK | → 0 | Neutral | 547.053 $ | +18.845 $ | +3,6 % | 1 | 528.208 $ | +528.208 $ | 1 | |||||
| BridgeBio Pharma, Inc. | BBIO | → 0 | Neutral | 223.440 $ | -222.120 $ | -49,9 % | 1 | 445.560 $ | -100.579 $ | -18,4 % | 1 | 546.139 $ | +546.139 $ | 1 | |
| Arcutis Biotherapeutics, Inc. | ARQT | → 0 | Neutral | 516.534 $ | +52.402 $ | +11,3 % | 1 | 464.132 $ | -79.381 $ | -14,6 % | 1 | 543.513 $ | +543.513 $ | 1 | |
| Kodiak Sciences Inc. | KOD | → 0 | Neutral | 233.760 $ | -147.440 $ | -38,7 % | 1 | 381.200 $ | -161.727 $ | -29,8 % | 1 | 542.927 $ | +542.927 $ | 1 | |
| Immunome Inc. | IMNM | → 0 | Neutral | 381.420 $ | -55.980 $ | -12,8 % | 1 | 437.400 $ | -104.863 $ | -19,3 % | 1 | 542.263 $ | +542.263 $ | 1 | |
| Aurinia Pharmaceuticals Inc. | AUPH | → 0 | Stark | 509.100 $ | +64.500 $ | +14,5 % | 1 | 444.600 $ | -96.950 $ | -17,9 % | 1 | 541.550 $ | +541.550 $ | 1 | |
| Mirum Pharmaceuticals, Inc. | MIRM | → 0 | Neutral | 292.675 $ | -169.225 $ | -36,6 % | 1 | 461.900 $ | -79.497 $ | -14,7 % | 1 | 541.397 $ | +541.397 $ | 1 | |
| EyePoint, Inc. | EYPT | → 0 | Neutral | 143.000 $ | +14.100 $ | +10,9 % | 1 | 128.900 $ | -410.613 $ | -76,1 % | 1 | 539.513 $ | +539.513 $ | 1 | |
| Alkermes plc. | ALKS | → 0 | Stark | 314.370 $ | +102.210 $ | +48,2 % | 1 | 212.160 $ | -327.294 $ | -60,7 % | 1 | 539.454 $ | +539.454 $ | 1 | |
| IONIS PHARMACEUTICALS INC | IONS | → 0 | Schwach | 539.172 $ | +28.560 $ | +5,6 % | 1 | 510.612 $ | -27.336 $ | -5,1 % | 1 | 537.948 $ | +537.948 $ | 1 | |
| Mineralys Therapeutics, Inc. | MLYS | → 0 | Neutral | 537.745 $ | +537.745 $ | 1 | |||||||||
| Arcellx, Inc. | ACLX | → 0 | 536.205 $ | +536.205 $ | 1 | ||||||||||
| PTC THERAPEUTICS, INC. | PTCT | → 0 | Neutral | 489.420 $ | +80.640 $ | +19,7 % | 1 | 408.780 $ | -126.434 $ | -23,6 % | 1 | 535.214 $ | +535.214 $ | 1 | |
| Zymeworks Inc. | ZYME | → 0 | Schwach | 261.400 $ | +11.000 $ | +4,4 % | 1 | 250.400 $ | -284.415 $ | -53,2 % | 1 | 534.815 $ | +534.815 $ | 1 | |
| SUPERNUS PHARMACEUTICALS, INC. | SUPN | → 0 | Stark | 279.060 $ | -31.080 $ | -10,0 % | 1 | 310.140 $ | -224.533 $ | -42,0 % | 1 | 534.673 $ | +534.673 $ | 1 | |
| Protagonist Therapeutics, Inc | PTGX | → 0 | Neutral | 367.740 $ | +51.540 $ | +16,3 % | 1 | 316.200 $ | -218.408 $ | -40,9 % | 1 | 534.608 $ | +534.608 $ | 1 | |
| Harmony Biosciences Holdings, Inc. | HRMY | → 0 | Stark | 364.100 $ | -35.967 $ | -9,0 % | 1 | 400.067 $ | -134.403 $ | -25,1 % | 1 | 534.470 $ | +534.470 $ | 1 | |
| Roivant Sciences Ltd. | ROIV | → 0 | Schwach | 534.276 $ | +534.276 $ | 1 | |||||||||
| Amylyx Pharmaceuticals, Inc. | AMLX | → 0 | Neutral | 194.650 $ | +44.002 $ | +29,2 % | 1 | 150.648 $ | -383.566 $ | -71,8 % | 1 | 534.214 $ | +534.214 $ | 1 | |
| Liquidia Corp | LQDA | → 0 | Schwach | 398.650 $ | -135.428 $ | -25,4 % | 1 | 534.078 $ | +534.078 $ | 1 | |||||
| Tarsus Pharmaceuticals, Inc. | TARS | → 0 | Schwach | 440.580 $ | -50.470 $ | -10,3 % | 1 | 491.050 $ | -42.726 $ | -8,0 % | 1 | 533.776 $ | +533.776 $ | 1 | |
| PALVELLA THERAPEUTICS, INC. | PVLA | → 0 | Neutral | 532.142 $ | +532.142 $ | 1 | |||||||||
| INSMED Inc | INSM | → 0 | Neutral | 530.648 $ | +530.648 $ | 1 | |||||||||
| Legend Biotech Corp | LEGN | → 0 | Neutral | 217.080 $ | -313.311 $ | -59,1 % | 1 | 530.391 $ | +530.391 $ | 1 | |||||
| NEUROCRINE BIOSCIENCES INC | NBIX | → 0 | Stark | 505.605 $ | -1.331 $ | -0,3 % | 1 | 506.936 $ | -22.657 $ | -4,3 % | 1 | 529.593 $ | +529.593 $ | 1 | |
| Nuvalent, Inc. | NUVL | → 0 | 529.204 $ | +529.204 $ | 1 | ||||||||||
| Viridian Therapeutics, Inc.\DE | VRDN | → 0 | Neutral | 528.013 $ | +528.013 $ | 1 | |||||||||
| ACADIA PHARMACEUTICALS INC | ACAD | → 0 | Neutral | 500.080 $ | +60.089 $ | +13,7 % | 1 | 439.991 $ | -87.959 $ | -16,7 % | 1 | 527.950 $ | +527.950 $ | 1 | |
| Wave Life Sciences, Inc. | WVE | → 0 | 527.680 $ | +527.680 $ | 1 | ||||||||||
| Stoke Therapeutics, Inc. | STOK | → 0 | Neutral | 392.640 $ | +1.920 $ | +0,5 % | 1 | 390.720 $ | -136.831 $ | -25,9 % | 1 | 527.551 $ | +527.551 $ | 1 | |
| Apogee Therapeutics, Inc. | APGE | → 0 | Neutral | 210.425 $ | -316.727 $ | -60,1 % | 1 | 527.152 $ | +527.152 $ | 1 | |||||
| Crinetics Pharmaceuticals, Inc. | CRNX | → 0 | Schwach | 411.620 $ | +12.100 $ | +3,0 % | 1 | 399.520 $ | -127.240 $ | -24,2 % | 1 | 526.760 $ | +526.760 $ | 1 | |
| UNITED THERAPEUTICS Corp | UTHR | → 0 | Stark | 207.543 $ | -318.687 $ | -60,6 % | 1 | 526.230 $ | +526.230 $ | 1 | |||||
| Maze Therapeutics, Inc. | MAZE | → 0 | Neutral | 525.001 $ | +525.001 $ | 1 | |||||||||
| Kymera Therapeutics, Inc. | KYMR | → 0 | Neutral | 458.680 $ | -66.047 $ | -12,6 % | 1 | 524.727 $ | +30.789 $ | +6,2 % | 1 | 493.938 $ | +493.938 $ | 1 | |
| Dianthus Therapeutics, Inc. /DE/ | DNTH | → 0 | Neutral | 243.700 $ | -175.900 $ | -41,9 % | 1 | 419.600 $ | -104.797 $ | -20,0 % | 1 | 524.397 $ | +524.397 $ | 1 | |
| Denali Therapeutics Inc. | DNLI | → 0 | Neutral | 217.668 $ | -306.723 $ | -58,5 % | 1 | 524.391 $ | +524.391 $ | 1 | |||||
| ALNYLAM PHARMACEUTICALS, INC. | ALNY | → 0 | Neutral | 441.009 $ | -43.716 $ | -9,0 % | 1 | 484.725 $ | -39.378 $ | -7,5 % | 1 | 524.103 $ | +524.103 $ | 1 | |
| EXELIXIS, INC. | EXEL | → 0 | Stark | 435.280 $ | -77.170 $ | -15,1 % | 1 | 512.450 $ | -11.231 $ | -2,1 % | 1 | 523.681 $ | +523.681 $ | 1 | |
| Xenon Pharmaceuticals Inc. | XENE | → 0 | Neutral | 253.512 $ | +9.282 $ | +3,8 % | 1 | 244.230 $ | -279.178 $ | -53,3 % | 1 | 523.408 $ | +523.408 $ | 1 | |
| NewAmsterdam Pharma Co N.V. | NAMS | → 0 | Schwach | 406.680 $ | -73.470 $ | -15,3 % | 1 | 480.150 $ | -43.244 $ | -8,3 % | 1 | 523.394 $ | +523.394 $ | 1 | |
| Celcuity Inc. | CELC | → 0 | Schwach | 228.280 $ | -294.757 $ | -56,4 % | 1 | 523.037 $ | +523.037 $ | 1 | |||||
| Kiniksa Pharmaceuticals International, plc | KNSA | → 0 | Neutral | 319.750 $ | -113.600 $ | -26,2 % | 1 | 433.350 $ | -88.669 $ | -17,0 % | 1 | 522.019 $ | +522.019 $ | 1 | |
| BIOMARIN PHARMACEUTICAL INC | BMRN | → 0 | Neutral | 521.320 $ | +521.320 $ | 1 | |||||||||
| OCULAR THERAPEUTIX, INC | OCUL | → 0 | Schwach | 147.300 $ | +20.250 $ | +15,9 % | 1 | 127.050 $ | -393.185 $ | -75,6 % | 1 | 520.235 $ | +520.235 $ | 1 | |
| MADRIGAL PHARMACEUTICALS, INC. | MDGL | → 0 | Schwach | 322.170 $ | +8.088 $ | +2,6 % | 1 | 314.082 $ | -205.365 $ | -39,5 % | 1 | 519.447 $ | +519.447 $ | 1 | |
| Syndax Pharmaceuticals Inc | SNDX | → 0 | Schwach | 437.200 $ | -30.000 $ | -6,4 % | 1 | 467.200 $ | -52.083 $ | -10,0 % | 1 | 519.283 $ | +519.283 $ | 1 | |
| Spyre Therapeutics, Inc. | SYRE | → 0 | Neutral | 355.120 $ | +94.900 $ | +36,5 % | 1 | 260.220 $ | -258.698 $ | -49,9 % | 1 | 518.918 $ | +518.918 $ | 1 | |
| Viking Therapeutics, Inc. | VKTX | → 0 | Neutral | 390.100 $ | -98.000 $ | -20,1 % | 1 | 488.100 $ | -29.539 $ | -5,7 % | 1 | 517.639 $ | +517.639 $ | 1 | |
| Immunovant, Inc. | IMVT | → 0 | Neutral | 500.890 $ | +23.962 $ | +5,0 % | 1 | 476.928 $ | -39.225 $ | -7,6 % | 1 | 516.153 $ | +516.153 $ | 1 | |
| Beam Therapeutics Inc. | BEAM | → 0 | Schwach | 508.218 $ | +508.218 $ | 1 | |||||||||
| AGIOS PHARMACEUTICALS, INC. | AGIO | → 0 | Neutral | 507.450 $ | +507.450 $ | 1 | |||||||||
| RHYTHM PHARMACEUTICALS, INC. | RYTM | → 0 | Schwach | 222.060 $ | -285.096 $ | -56,2 % | 1 | 507.156 $ | +507.156 $ | 1 | |||||
| Vera Therapeutics, Inc. | VERA | → 0 | Schwach | 300.370 $ | -101.930 $ | -25,3 % | 1 | 402.300 $ | -103.897 $ | -20,5 % | 1 | 506.197 $ | +506.197 $ | 1 | |
| Inhibrx Biosciences, Inc. | INBX | → 0 | Sehr schwach | 465.702 $ | -39.029 $ | -7,7 % | 1 | 504.731 $ | +504.731 $ | 1 | |||||
| CRISPR Therapeutics AG | CRSP | → 0 | Schwach | 272.700 $ | -179.215 $ | -39,7 % | 1 | 451.915 $ | -50.460 $ | -10,0 % | 1 | 502.375 $ | +502.375 $ | 1 | |
| Immunocore Holdings plc | IMCR | → 0 | Neutral | 480.727 $ | +24.226 $ | +5,3 % | 1 | 456.501 $ | -44.156 $ | -8,8 % | 1 | 500.657 $ | +500.657 $ | 1 | |
| Axsome Therapeutics, Inc. | AXSM | → 0 | Sehr schwach | 244.770 $ | -236.092 $ | -49,1 % | 1 | 480.862 $ | +480.862 $ | 1 | |||||
| ARDELYX, INC. | ARDX | → 0 | Neutral | 306.000 $ | -173.200 $ | -36,1 % | 1 | 479.200 $ | +479.200 $ | 1 | |||||
| Upstream Bio, Inc. | UPB | → 0 | Schwach | 478.763 $ | +478.763 $ | 1 | |||||||||
| Olema Pharmaceuticals, Inc. | OLMA | → 0 | Schwach | 125.100 $ | -24.000 $ | -16,1 % | 1 | 149.100 $ | -327.475 $ | -68,7 % | 1 | 476.575 $ | +476.575 $ | 1 | |
| Cogent Biosciences, Inc. | COGT | → 0 | Neutral | 464.400 $ | +2.520 $ | +0,5 % | 1 | 461.880 $ | -8.156 $ | -1,7 % | 1 | 470.036 $ | +470.036 $ | 1 | |
| Structure Therapeutics Inc. | GPCR | → 0 | Schwach | 467.306 $ | +467.306 $ | 1 | |||||||||
| Dyne Therapeutics, Inc. | DYN | → 0 | Schwach | 444.200 $ | +81.600 $ | +22,5 % | 1 | 362.600 $ | -58.625 $ | -13,9 % | 1 | 421.225 $ | +421.225 $ | 1 | |
| ARROWHEAD PHARMACEUTICALS, INC. | ARWR | → 0 | Neutral | 211.926 $ | -232.157 $ | -52,3 % | 1 | 444.083 $ | +444.083 $ | 1 | |||||
| ALUMIS INC. | ALMS | → 0 | Neutral | 427.185 $ | +427.185 $ | 1 | |||||||||
| COMPASS Pathways plc | CMPS | → 0 | Neutral | 254.700 $ | -137.930 $ | -35,1 % | 1 | 392.630 $ | +392.630 $ | 1 | |||||
| Enliven Therapeutics, Inc. | ELVN | → 0 | Neutral | 355.250 $ | +80.850 $ | +29,5 % | 1 | 274.400 $ | +274.400 $ | 1 | |||||
| Intellia Therapeutics, Inc. | NTLA | → 0 | Neutral | 338.400 $ | -6.458 $ | -1,9 % | 1 | 344.858 $ | +344.858 $ | 1 | |||||
| Tango Therapeutics, Inc. | TNGX | → 0 | Schwach | 312.600 $ | +11.352 $ | +3,8 % | 1 | 301.248 $ | +301.248 $ | 1 | |||||
| Oruka Therapeutics, Inc. | ORKA | → 0 | Neutral | 285.510 $ | +41.830 $ | +17,2 % | 1 | 243.680 $ | +243.680 $ | 1 | |||||
| Erasca, Inc. | ERAS | → 0 | Schwach | 280.351 $ | +280.351 $ | 1 | |||||||||
| Krystal Biotech, Inc. | KRYS | → 0 | Neutral | 257.196 $ | +257.196 $ | 1 | |||||||||
| ArriVent BioPharma, Inc. | AVBP | → 0 | Schwach | 244.604 $ | +244.604 $ | 1 | |||||||||
| KalVista Pharmaceuticals, Inc. | KALV | → 0 | 217.303 $ | +217.303 $ | 1 | ||||||||||
| Scholar Rock Holding Corp | SRRK | → 0 | Neutral | 210.485 $ | +210.485 $ | 1 | |||||||||
| Edgewise Therapeutics, Inc. | EWTX | → 0 | Neutral | 203.150 $ | -1.600 $ | -0,8 % | 1 | 204.750 $ | +204.750 $ | 1 | |||||
| Summit Therapeutics Inc. | SMMT | → 0 | Neutral | 193.828 $ | +193.828 $ | 1 | |||||||||
| Oric Pharmaceuticals, Inc. | ORIC | → 0 | Sehr schwach | 140.790 $ | -23.920 $ | -14,5 % | 1 | 164.710 $ | +164.710 $ | 1 | |||||
| Compass Therapeutics, Inc. | CMPX | → 0 | Stark | 158.700 $ | +158.700 $ | 1 | |||||||||
| CytomX Therapeutics, Inc. | CTMX | → 0 | Stark | 147.750 $ | +147.750 $ | 1 | |||||||||
| 117.413.190 $ | +52.629.622 $ | -2,0 % | 74 | 70.867.716 $ | +40.339.176 $ | -22,7 % | 78 | 44.153.671 $ | +44.153.671 $ | 84 | |||||